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Evidence for two modes of cooperative DNA binding in vivo that
do not involve direct protein–protein interactions
Sanjay Vashee*, Karsten Melcher†, W. Vivianne Ding†, Stephen Albert
Johnston† and Thomas Kodadek†
Background: The promoter regions of most eukaryotic genes contain binding
sites for more than one transcriptional activator and these activators often bind
cooperatively to promoters. The most common type of cooperativity is supported
by direct protein–protein interactions. Recent studies have shown that proteins
that do not specifically interact with one another can bind cooperatively to
chromatin in vitro, probably by the localized destabilization of nucleosome
structure by one factor, facilitating binding of another to a nearby site. This
mechanism does not require that the transcription factors have activation
domains. We have examined whether this phenomenon occurs in vivo.
Results: Unrelated non-interacting proteins can bind DNA cooperatively in
yeast cells; this cooperative binding can contribute significantly to
transcriptional activation, does not require that both factors have activation
domains and is only operative over relatively short distances. In addition to this
‘short-range’ mechanism, unrelated non-interacting proteins can bind
cooperatively to sites separated by hundreds of base pairs, so long as both
have potent activation domains.
Conclusion: Cooperative binding of transcription factors in vivo can occur by
several mechanisms, some of which do not require direct protein–protein
interactions and which cannot be detected in vitro using naked DNA templates.
These findings must be taken into account when evaluating mechanisms for
synergistic transcriptional activation. 
Background
Most eukaryotic genes have complex promoters that
contain binding sites for different positive and negative reg-
ulatory factors [1] and these transcription factors can inter-
act functionally with one another. A particularly common
observation is that the effect of two or more transcriptional
activators working in concert on a promoter is greater than
the sum of their individual activities. In many cases, this
synergy is consistent with the observation of cooperative
binding of the transcription factors to DNA in vitro [2–5],
but many observations of synergistic effects in vivo have
been reported for activators that do not bind cooperatively
to naked DNA templates in vitro. This has led to the pro-
posal of fundamentally different models for synergistic acti-
vation in which either protein–protein interactions or
protein–DNA interactions are limiting [6–8]. Most of these
models propose either that high-level transcription requires
multiple interactions of the activator with general transcrip-
tion factors which can only be satisfied by several activators,
or that different activators may stimulate different partially
rate-limiting steps, leading to ‘kinetic synergy’ [9].
Experiments using DNA bound by core nucleosomes
have shown that proteins that do not interact with one
another specifically and that are unrelated — and there-
fore unlikely to bind to the same sites on DNA —
nonetheless bind cooperatively to closely spaced DNA
sites in vitro [10]. This may be due to localized destabiliza-
tion of nucleosome structure by one factor, which
enhances the ability of a second binding protein to
compete with histones for a nearby site [11,12]. In larger
DNA substrates with multiple nucleosomes, binding of
one high-affinity factor could act as a positioning element,
making it much more likely that a nearby site would
remain nucleosome free. This ‘non-traditional’ explana-
tion for cooperative binding of transcription factors to pro-
moters could explain, at least in part, many observations of
synergistic activation. Recently, Chavez and Beato [13]
used footprinting experiments to demonstrate a clear-cut
case of cooperative binding in vivo of two activators that
do not bind naked DNA cooperatively in vitro; their work
supports the biological relevance of using nucleosome-
bound DNA in experiments studying cooperative binding
in vitro.
In this report, we examine in more detail the mechanism
of cooperative binding between unrelated transcription
factors, using the Saccharomyces cerevisiae Gal4 protein
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(Gal4p), a potent activator of genes involved in galactose
metabolism, and derivatives of the Escherichia coli LexA
protein. These proteins do not interact with one another
directly and, as expected, do not bind cooperatively to
naked DNA templates in vitro. It is shown that Gal4p and
LexA protein derivatives do bind cooperatively to plas-
mids bearing the appropriate sites in yeast cells, however.
There appear to be two distinct mechanisms for coopera-
tivity: one is ‘short-range’ and may be the result of nucleo-
some destabilization or repositioning as discussed above.
The other can operate over distances of at least several
hundred base pairs and requires that both factors have
potent activation domains. The biological implications of
these data are discussed. 
Results and discussion
Gal4p and LexA bind to DNA cooperatively in yeast 
S. cerevisiae Gal4p is a prototypical transcriptional activator
that stimulates the expression of several genes involved in
galactose metabolism [14,15]. Recently, a simple method
was developed to measure binding of Gal4p to DNA
quantitatively in vivo. This ‘plasmid titration’ assay [16,17]
takes advantage of the fact that expression of the native
MEL1 gene, which encodes α-galactosidase, is limited by
binding of the low abundance Gal4p to the single low-
affinity upstream activation sequence (UAS) in the pro-
moter. Introduction of plasmids bearing Gal4p-binding
sites decreased the expression of the MEL1 gene
(Figure 1a) because the plasmid-borne binding sites
compete for limiting endogenous Gal4p. The magnitude
of the inhibitory effect was related linearly to the number
of plasmid molecules introduced and the affinity of Gal4p
for the plasmid-borne site (H.E. Xu, Q. Li, A. Vonica,
T.K. and S.A.J., unpublished observations). For example,
transformation of yeast with plasmids that carry a single,
high-affinity [17,18], consensus Gal4p-binding site (cUAS;
[19]) and are maintained at about either 12 or 25 copies
per cell, resulted in inhibition of MEL1 transcription by
10% and 20%, respectively (Figure 1b). When the plas-
mids carried the low-affinity [17,18] MEL1 UAS
(UASMEL1), very little inhibition of MEL1 expression was
observed (0% and 3%, respectively; Figure 1b).
The same titration assay was used to ask whether the
nearby binding of the bacterial LexA protein would influ-
ence the binding of Gal4p to its recognition site. The
experiments were conducted in a yeast strain overexpress-
ing the LexA DNA-binding domain (LexA DBD) [20].
This protein binds its cognate operator (OLex) with high
affinity, but does not activate transcription in yeast. As
LexA is a bacterial protein, it seems highly unlikely that it
makes specific contacts with Gal4p of the type that would
support cooperative DNA binding. As shown in Figure 1b,
however, titration plasmids carrying the UASMEL1 and
OLex sequences separated by 29 base pairs were much
more effective competitors of MEL1 expression than those
carrying only UASMEL1: binding of Gal4p to UASMEL1 was
stimulated 6–10-fold. Quantitative Southern blots demon-
strated that the average copy number of the titration plas-
mids was unaffected by the presence of the OLex (data not
shown). Plasmids bearing the OLex site, but no Gal4p
recognition sequence, had little effect on MEL1 expres-
sion (Figure 1b). These data argue that Gal4p and
LexA DBD bind to the titration plasmids cooperatively. 
A logical extension of this cooperative binding argument is
that the presence of OLex would have less influence on the
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Figure 1
Gal4p and the LexA DNA-binding domain (LexA DBD) bind to plasmid
DNA cooperatively in yeast. (a) The plasmid titration assay, which
measures the decrease in MEL1 expression due to the introduction of
plasmids carrying Gal4p-binding sites. In this experiment, the effect of
introducing plasmids bearing either the low-affinity Gal4p-binding site
UASMEL1 or the high-affinity cUAS site was assessed in cases where
the plasmids either did or did not also have a LexA-binding site (OLex)
located 29 bp away from the Gal4p-binding site. (b) Results from
plasmid titration assays probing the effect of a nearby LexA DBD–OLex
complex on the affinity of Gal4p for cUAS or UASMEL1. Experiments
were done with plasmids that were identical except for the copy
number at which they were maintained. The LexA DBD–OLex complex
stimulates binding to UASMEL1 strongly and has a slight stimulatory
effect on Gal4p–cUAS association. This is consistent with cooperative
binding. When MEL1 expression was not inhibited, the α-
galactosidase activity was about 600 units. Mean values are given
above bars; the data showed 5% variation.
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ability of Gal4p to occupy a high-affinity UAS, as coopera-
tivity is less important for occupancy of a strong site.
Indeed, when the weak MEL1 site was replaced with the
high-affinity cUAS site, the presence of a nearby
LexA DBD–OLex complex had less than a twofold effect
on Gal4p occupancy (Figure 1b).
A nearby LexA DBD–OLex complex stimulates Gal4p-
mediated transcription 
To look for further evidence of cooperative binding of
LexA DBD and Gal4p and to ask whether the effects
observed in the plasmid titration experiment are relevant
to promoter occupancy, the experiment shown in Figure 2
was carried out. The same yeast strain was transformed
with a lacZ reporter plasmid whose promoter contains
single UASMEL1 and OLex sites separated by 29 base pairs.
The level of β-galactosidase expression supported by this
plasmid was compared with that obtained using a reporter
plasmid that lacked the OLex site, but was otherwise iden-
tical. The presence of a nearby LexA DBD–OLex complex
was found to stimulate Gal4p-mediated lacZ expression by
about fourfold when transcription was driven by the weak
UASMEL1 (Figure 2b). This is in reasonable agreement
with the 6–10-fold increase in DNA-binding affinity
observed in the plasmid titration assay. As expected,
almost no β-galactosidase activity was observed when the
plasmid contained only an OLex site. These data provide
further evidence that a nearby LexA DBD–DNA complex
stimulates Gal4p binding in vivo and demonstrate that this
effect can accentuate the level of Gal4p-mediated tran-
scription supported by a low-affinity binding site. They
also show how a protein that is itself not an activator
(LexA DBD) can contribute significantly to expression of
the target gene by facilitating occupancy of the promoter
by a true activator.
The most common mechanism for cooperative DNA
binding involves direct association between the two DNA-
binding proteins. Though this seems unlikely for yeast
Gal4p and bacterial LexA DBD, in vitro DNA-binding
experiments were carried out to test this possibility. A
DNA fragment corresponding to the UASMEL1 + OLex pro-
moter element used in the experiment shown in Figure 2
was radiolabeled. This fragment was then incubated with a
constant amount of yeast extract from a gal4– LexA DBD+
strain and increasing amounts of extract from a GAL4+
lexA DBD– strain. Extracts were used, rather than purified
proteins, in case another protein somehow contributed to
cooperative binding. If Gal4p and LexA DBD bind DNA
cooperatively by interacting with each other, then Gal4p
should have a higher affinity for the LexA DBD–DNA
complex than for naked DNA; however, gel retardation
experiments revealed that Gal4p bound naked DNA and
the LexA DBD–DNA complex with approximately equal
affinities (Figure 3), confirming the expectation that Gal4p
and LexA DBD do not bind to naked DNA cooperatively.
Evidence for two distinct mechanisms of cooperative
binding between Gal4p and LexA derivatives
A distinguishing feature of the simple nucleosome-medi-
ated cooperativity observed by Adams and Workman [10]
in vitro was that the degree of cooperativity was strongly
distance dependent, but was not affected by the presence
or absence of an activation domain. To ask if the coopera-
tivity observed in vivo between LexA DBD and Gal4p can
be explained completely by this mechanism, these para-
meters were investigated. Figure 4 (open squares) illus-
trates that cooperative DNA binding by LexA DBD and
Gal4p in vivo was diminished considerably when the sites
were separated by 200 base pairs and essentially abolished
at 400 base pairs, consistent with a simple core nucleo-
some destabilization model. 
Fusion of the activation domain of the herpes simplex
virus VP16 protein [21–23] to LexA DBD, however,
increased the degree of cooperativity about twofold over
that observed using LexA DBD alone (Figure 4; the OLex
and UAS sites were separated by 29 base pairs). Note that
the data in Figure 4 were normalized to a control in which
the titration plasmid carried neither a Gal4p- nor LexA-
binding site, thus correcting for the somewhat lower level
of transcriptional activity due to general squelching by the
454 Current Biology, Vol 8 No 8
Figure 2
The reporter gene shown in (a) was used to monitor (b) the effect of
LexA DBD–OLex complex formation on transcription mediated by a
nearby low-affinity Gal4p-binding site (UASMEL1). Gal4p was activated
in all experiments by growth in galactose. The strain used expressed
large amounts of LexA DBD. The mean of at least three independent
measurements is shown; the data showed 13% variation. The distance
between the LexA and Gal4p sites was 29 bp, with the latter located
approximately 200 bp upstream of the lacZ transcriptional start site.
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LexA–VP16 fusion protein. Thus, the differences in
MEL1 inhibition in the presence and absence of the VP16
activation domain cannot be ascribed to a generic
inhibitory effect due to titration of some limiting
transcription factor. Again, DNA-binding experiments
using LexA–VP16 and lysates made from Gal4p-express-
ing yeast showed that these proteins do not bind to naked
DNA cooperatively in vitro (data not shown). In striking
contrast to LexA DBD, LexA–VP16 exhibited highly
cooperative binding with Gal4p in vivo even when
UASMEL1 and OLex were separated by 200 or 400 base
pairs (Figure 4, closed diamonds). These results are not
predicted by a simple core-nucleosome-displacement
model of the type shown in Figure 5. 
Thus, the data argue that there are at least two mecha-
nisms for cooperative binding in vivo of Gal4p and pro-
teins containing LexA DBD. One mechanism has a sharp
dependence on the separation between the DNA sites
involved and does not require that LexA DBD be fused to
an activation domain. The other mechanism is distance
insensitive, at least over the 400 base-pair range
examined, and requires that both proteins have an activa-
tion domain. The latter mechanism supports a somewhat
higher degree of cooperativity. Neither requires direct and
specific interactions between the proteins.
Figure 3
Gel retardation experiments reveal that Gal4p and LexA DBD do not
bind naked DNA cooperatively in vitro. Increasing amounts of extract
from a GAL4+ lexA DBD– strain were incubated with the UAS + OLex
probe in the absence (lanes 2–5) or presence (lanes 7–10) of a
constant amount of extract from a gal4– LexA DBD+ strain. Sufficient
gal4– LexA DBD+ extract was added to approximately half-saturate the
OLex site. PhosphorImager quantitation of the free DNA probe and of
DNA–LexA complexes is shown below the autoradiogram and reveals
that Gal4p binds to the naked DNA and the DNA–LexA complex with
about equal affinity. No cooperativity was observed. The Gal4p-
containing complexes were unstable at higher Gal4p concentrations
presumably because Gal4p can form higher-order complexes that
dissociate during electrophoresis. Gal4ptrunc–DNA is a complex
between DNA and an amino-terminal proteolytic fragment of Gal4p as
determined by antibody supershifts (data not shown). The asterisk
indicates an unidentified complex. 
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Figure 4
Dependence of cooperativity on the distance (in bp) between
UASMEL1 and OLex, as measured by plasmid titration. The results
shown were obtained from at least three separate experiments in
which the plasmids were present at an average copy number per cell
of 12. For each set of experiments — using cells expressing high levels
of either LexA DBD or a fusion protein comprising LexA DBD and the
activation domain of VP16 (LexA–VP16) — the α-galactosidase
activities were normalized to those in a control experiment, using the
same cells, in which the titration plasmid contained neither a Gal4p-
nor a LexA-binding site. This corrected for the moderate amount of
squelching due to high-level expression of LexA–VP16. Therefore, the
higher level of MEL1 inhibition in the presence of LexA–VP16 was not
due to general squelching. The results argue that there are at least
two mechanisms that support non-traditional cooperative binding: a
‘short-range’ mechanism that does not require the presence of an
activation domain on the LexA protein and is strongly distance
dependent, and a ‘long-range’ mechanism that requires the presence
of the VP16 activation domain. 
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Possible molecular mechanisms for cooperative binding
In considering models for these cooperative binding phe-
nomena, it is assumed that LexA DBD and LexA–VP16
essentially saturate the plasmid sites in vivo. This assump-
tion is supported by the fact that these proteins were
expressed from the strong ADH1 promoter, LexA DBD
has a very high affinity for OLex and LexA–VP16 is a potent
activator in yeast cells [24]. It is also consistent with in vivo
footprinting data (S.V. and T.K., unpublished observa-
tions) which, while not very quantitative, show occupancy
of OLex. The situation in these experiments is therefore
one of a stably bound LexA chimera helping to recruit
Gal4p to a low-affinity site. As mentioned, the short-range
mechanism is probably due to the fundamentally coopera-
tive nature of two proteins binding to a single core nucleo-
some (Figure 5). A related possibility is that stable binding
of LexA DBD creates a boundary that positions otherwise
randomly situated nucleosomes on the plasmid in a way
that promotes Gal4p binding to nearby sites.
Fusion of the activation domain of VP16 to LexA DBD
doubles the magnitude of the observed cooperativity and,
more importantly, renders cooperative binding insensitive
to the distance between the Gal4p and LexA binding
sites. There have been previous reports that the presence
of an activation domain can enhance binding of a single
transcriptional activator to simple promoters with sites for
only that protein [16,25]. The molecular basis of this effect
is not completely clear, but it has been speculated that
direct contacts between activation domains and transcrip-
tion factors support cooperative binding of the polymerase
II holoenzyme and the activator. As the activation domain
of VP16 has been reported to interact with a histone acety-
lase complex [26,27], stable binding of the LexA–VP16
fusion to the OLex site might modify the chromatin struc-
ture over an extended area, thus enhancing binding of
Gal4p to its cognate UAS (Figure 6a). It may also be that
the activation domain of VP16 recruits the Swi/Snf chro-
matin remodeling complex [28–31], which is thought to
facilitate transcription-factor binding to chromatinized
DNA [32–35]. Whether or not such a model is compatible
with the observation that cooperativity is retained even
when the protein binding sites are separated by several
hundred base pairs is unclear, as the ‘range’ over which
these chromatin remodeling machines might influence
factor binding has not been studied carefully. 
An alternative model, that different transcriptional activa-
tors have nonoverlapping targets in the polymerase II
holoenzyme, has been proposed [6,7]. If so, Gal4p and
LexA–VP16 could contact one another indirectly via a
‘protein bridge’ (Figure 6b), thus supporting cooperative
binding. This kind of idea has been put forward to ratio-
nalize synergistic activation, but with the important
difference that high-affinity DNA–protein interactions
were proposed to support weak protein–protein contacts.
If this model is operative in the experiments reported
here, the opposite is true; strong protein–protein contacts
help to anchor a weak Gal4p–DNA interaction. One argu-
ment against this model is that cooperativity was observed
in the plasmid titration experiments even though there
was no promoter near the Gal4p and LexA–VP16 binding
sites. This argument is tempered, however, by the fact
Figure 5
A possible activation-domain-independent
mechanism to rationalize cooperative binding
of Gal4p and LexA DBD in vivo. LexA is
proposed to ‘loosen’ the structure of the
nucleosome (brown) in the immediate vicinity
of OLex (dark gray box), facilitating binding of
Gal4p to a nearby site. This type of model has
been discussed previously [10,12].
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Figure 6
Models for activation-domain-dependent cooperative binding in vivo.
(a) Activation-domain-dependent recruitment of a chromatin-
remodeling or chromatin-modification complex. Brown circles are
nucleosomes. The white arrow indicates that the remodeling complex
modifies the chromatin structure in some way. (b) Activation-domain-
dependent bridging by a complex (red) to which the VP16 and Gal4p
activation domains bind in a non-overlapping fashion.
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that the plasmid does contain a distant URA3 promoter
which could harbor a holoenzyme complex that might
interact with the activators. Northern blots of URA3
expression did not reveal any effect due to the presence of
Gal4p and LexA–VP16 (data not shown), but this is not
conclusive evidence against a bridged interaction involv-
ing a transcription complex at this promoter. Further
investigation will be necessary to distinguish between
various models for the mechanism of this cooperative acti-
vation-domain-dependent binding.
Conclusions 
Our findings have important implications in understand-
ing how multiple transcription factors could interact to
modulate the level of expression of target genes. The data
reported support the general idea that binding of proteins
to nearby sites in vivo is inherently cooperative, as sug-
gested originally by work in vitro and a single study in
vivo. A cooperative DNA-binding mechanism cannot
therefore be ruled out simply because two factors do not
bind cooperatively to naked DNA in vitro. Another conse-
quence of the short-range mechanism of cooperative
binding is that not all proteins that contribute to the acti-
vation of gene expression need themselves be activators:
the fact that the presence of a nearby LexA DBD–OLex
complex stimulated Gal4p-mediated transcription
(Figure 2), even though LexA DBD is not itself an activa-
tor, is evidence of this. The role of the LexA DBD–OLex
complex was to stimulate occupancy of the true activator,
Gal4p. A related example of non-traditional cooperativity,
but one which uses a different mechanism, has been
reported by Grosschedl and colleagues [36]. They demon-
strated that the LEF-1 protein, which contributes to the
activation of the TCRα gene, is not a true activator, but
instead bends DNA severely, promoting cooperative
binding of two other factors whose binding sites are
brought into proximity by the bend. 
The second mode of cooperative DNA binding that we
have found evidence for depends on both proteins having
activation domains and operates over a longer range. This
mechanism of cooperative binding might go far in explain-
ing synergistic effects observed between different activa-
tors that individually stimulate gene expression only
weakly, if the individual activities are limited by promoter
occupancy. Elucidation of the detailed mechanism(s)
supporting this mode of cooperative binding will require
further work. 
Materials and methods 
Reporter gene experiments
Derivatives of pJLb, which contains a β-galactosidase gene under the
control of a CYC1 core promoter, were used. The derivatives contained
either a single OLex (5′-GTACTGTATGTACATACAGTAC-3′), a single
UASMEL1 (5′-CGGCCATATGTCTTCCG-3′) or OLex and UASMEL1 sepa-
rated by 29 bp. The sites were approximately 200 bp from the transcrip-
tion start site. LexA DBD was expressed from the ADH1 promoter in
pEG202 (gift from Roger Brent, Harvard Medical School). Plasmids
were transformed into yeast strain Sc18 and grown in the appropriate
media with 2% galactose, 3% glycerol and 2% lactic acid as the carbon
source. β-galactosidase assays were performed as described [16].
Plasmid titration assays
Plasmid titration assays were carried out as described previously [16].
The plasmids employed were derivatives of YEp352 (average copy
number 12) and YEp351 (average copy number 25). Oligonucleotides
containing either a single OLex, a UASMEL1 or a cUAS (5′-CGGAG-
GACTGTCCTCCG-3′) site were inserted into these vectors. These
derivatives were then employed to place an OLex and either a cUAS or
a UASMEL1 site in the same vector. When both OLex and UASMEL1 sites
were present, they were separated either by 29, 200 or 400 bp. The
intervening DNA did not contain any native yeast sequences. Experi-
ments involving LexA DBD were performed in Sc18 while experiments
involving LexA–VP16 were performed in yeast strain 21R. When
present, LexA DBD and LexA–VP16 were expressed from a plasmid
under the control of the potent ADH1 promoter. The YEp-based titra-
tion plasmid together with the appropriate LexA-expressing plasmid
were transformed into yeast and grown in the appropriate medium with
2% galactose, 3% glycerol and 2% lactic acid as the carbon source.
In vitro DNA-binding experiments
The probe was isolated as a 100 bp PCR fragment from the same
reporter plasmid used for the in vivo experiments. The fragment was
end-labeled with Klenow and α-[32P]dATP and gel-purified. Gel shift
conditions and extract preparation were as described previously [37].
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